Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 3/20 | 0.74 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636536 | 0.99 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL636535 | 0.99 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL10528520 | 0.92 | SIRT2 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL18858917 | 0.91 | ENTPD1 (0.77) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL21283084 | 0.91 | ENTPD1 (0.77) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL9752397 | 0.91 | ENTPD1 (0.74) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL16805436 | 0.91 | ENTPD1 (0.77) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL18852609 | 0.91 | ENTPD1 (0.77) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL4314233 | 0.91 | ENTPD1 (0.72) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL9752399 | 0.91 | ENTPD1 (0.74) | ENTPD1TRPM2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253535-B2 | Carboline derivatives or phosphorous derivatives for the treatment of muscular myopathies and traumatic injuries to muscles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253535-B2 | Carboline derivatives or phosphorous derivatives for the treatment of muscular myopathies and traumatic injuries to muscles | NAMPT, SARM1, NNT | ENTPD1 65/4885TRPM2 942/4885P2RY1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.